United States

Takeda Pharmaceutical Co Ltd (4502.T)

4502.T on Tokyo Stock Exchange

2:00am EDT
Change (% chg)

¥71 (+1.25%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Latest Key Developments (Source: Significant Developments)

R&I removes Takeda Pharmaceutical from rating monitor and downgrades rating to "AA-" – R&I
Wednesday, 1 Mar 2017 01:33am EST 

Takeda Pharmaceutical Co Ltd <4502.T>: Rating and Investment Information, Inc. (R&I) removed the co from rating monitor - R&I . R&I downgraded its rating to "AA-" from "AA" - R&I .Rating outlook stable - R&I.  Full Article

Fujifilm Holdings offers ToB for 18.2 mln shares of Wako Pure Chemical Industries, Ltd.
Friday, 24 Feb 2017 01:18am EST 

Fujifilm Holdings Corp <4901.T>: Says the co offered a takeover bid for 18.2 million shares (or no less than 12.5 million shares) of Wako Pure Chemical Industries, Ltd., aiming to fully acquire it . Says offered purchase price at 8,535 yen per share . Takeover bid total amount at 155.47 billion yen . Offering period from Feb. 27 to April 3 .Settlement starts on April 21.  Full Article

Takeda Pharmaceutical to transfer consumer healthcare business to wholly owned unit
Monday, 20 Feb 2017 02:10am EST 

Takeda Pharmaceutical Co Ltd <4502.T>: Says the co plans to transfer domestic consumer healthcare business to its wholly owned unit, a Tokyo-based medical supplies firm .Says effective April 1.  Full Article

TiGenix and Takeda report new data on Cx601
Friday, 17 Feb 2017 03:01am EST 

TiGenix NV :TiGenix and Takeda <4502.T> report on Friday morning new data highlighting maintenance of long-term remission of complex perianal fistulas in Crohn's disease patients with Cx601.  Full Article

Takeda Pharmaceutical completes acquisition of ARIAD Pharmaceuticals
Friday, 17 Feb 2017 02:01am EST 

Takeda Pharmaceutical Co Ltd <4502.T> :Says co completes full acquisition of ARIAD Pharmaceuticals Inc on Feb. 16(U.S. local time), at $24.00 per share.  Full Article

Takeda Pharmaceutical & Ovid Therapeutics announces clinical development,commercialization collaboration for TAK-935
Wednesday, 18 Jan 2017 07:03am EST 

Takeda Pharmaceutical Co Ltd: Takeda and Ovid Therapeutics announce innovative clinical development, commercialization collaboration for TAK-935 in rare pediatric epilepsies . Takeda Pharmaceutical says received equity in Ovid and may be eligible to receive certain milestone payments based on the advancement of TAK-935 . Takeda Pharmaceutical says Takeda will lead commercialization in Japan, and has the option to lead in asia and other selected geographies . Takeda Pharmaceutical says Cos to share in development and commercialization costs on 50/50 basis; if successful, will share in profits on 50/50 basis . Takeda Pharmaceutical says if mutually agreed, additional orphan central nervous system indications may also be pursued . Takeda Pharmaceutical says Ovid will lead clinical development activities and commercialization of TAK-935 in the U.S., Europe, Canada and Israel . Takeda pharmaceutical says additional financial details were not disclosed .Takeda pharmaceutical says companies expect to initiate a phase 1B/2A study in 2017 in patients with rare epileptic encephalopathies.  Full Article

Maverick and Takeda announce 5 year collaboration to advance T-cell engagement therapies
Wednesday, 11 Jan 2017 08:00am EST 

Takeda Pharmaceutical Co Ltd <4502.T> : Maverick Therapeutics and Takeda announce five-year collaboration to advance T-cell engagement therapies . Takeda invests $125 million in Maverick, including exclusive option-to-acquire .Deal provides Takeda exclusive right to purchase Maverick after five years for an undisclosed sum.  Full Article

Ariad Pharma says termination fee for Takeda deal will be $169 mln
Tuesday, 10 Jan 2017 03:17pm EST 

Ariad Pharmaceuticals Inc:If deal is terminated by co, to enter definitive agreement with respect to superior proposal, co to pay termination fee of $169 million.  Full Article

R&I affirms Takeda Pharmaceutical's rating at "AA" and announces negative outlook – R&I
Monday, 26 Dec 2016 01:27am EST 

Takeda Pharmaceutical Co Ltd <4502.T>: Rating and Investment Information, Inc. (R&I) affirmed the company's rating at "AA" – R&I .Rating outlook negative– R&I.  Full Article

Tigenix submits day 120 responses to EMA for CX601 marketing authorization
Thursday, 22 Dec 2016 04:03pm EST 

Tigenix NV : Tigenix NV - Tigenix submits day 120 responses to European Medicines Agency for CX601 marketing authorization . Tigenix- expects to receive EMA day 180 list of outstanding issues in Feb 2017, anticipates decision from EMA on CX601 marketing approval during 2017 .Tigenix- if approved, would trigger the payment by Takeda to Tigenix of euro 15 million.  Full Article

More From Around the Web

BRIEF-Wilex says unit Heidelberg Pharma signs research agreement with Takeda